Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue: +3,749.2%
EPS: +549.1%
Free cash flow: +839.7%

Quarter to June 2026, against a year earlier

131.81 3.45 −2.55%

Follow PTGX

Alert me

Market cap: $8.8B
P/E: 108×
Fwd P/E: 31.2×
Dividend yield: —
F-score: 4/9
Altman Z: 61.55
Beneish M: −7.18
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Protagonist Therapeutics, Inc. 8-K filed Jun 18, 2026

Period ended Jun 17, 2026 · Filed Jun 18, 2026 · accepted 4:30 PM ET · Document on sec.gov · Filing index

5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits

Red flags

Officer departure Jun 18, 2026
Protagonist Therapeutics, Inc. reported the departure of an officer or director

8-K filed Jun 18, 2026 · The filing · sec.gov

Protagonist Therapeutics, Inc. 8-K filed Jun 18, 2026

Red flags

Stockrow Weekly